Coronary artery disease (CAD) is a leading cardiovascular condition caused by plaque buildup in the arteries, restricting blood flow to the heart. In 2022, there were approximately 315 million prevalent cases of coronary artery disease. There is a high unmet clinical need for better therapies, as current treatment options, such as statins and antiplatelet drugs, have limitations. The growing focus on novel coronary artery disease therapeutics, including PCSK9 inhibitors, anti-inflammatory agents, and regenerative therapies, is likely to drive pipeline growth. Advancements in personalized medicine and gene therapies further offer promising avenues for developing innovative coronary artery disease drug candidates.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to coronary artery disease.
Coronary artery disease treatment typically includes lifestyle changes, medications like statins and antiplatelet drugs, and in severe cases, surgical procedures such as angioplasty or coronary artery bypass surgery. These therapies aim to reduce symptoms, prevent complications, and improve heart function.
This product will be delivered within 3-5 business days.
Report Coverage
The Coronary Artery Disease Drug Pipeline Insight Report by the publisher gives comprehensive insights into coronary artery disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for coronary artery disease. The coronary artery disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The coronary artery disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with coronary artery disease treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to coronary artery disease.
Coronary Artery Disease Drug Pipeline Outlook
Coronary artery disease (CAD) occurs when plaque builds up in the coronary arteries, narrowing and hardening them, which limits blood flow to the heart. This condition often results from atherosclerosis, where fatty deposits, cholesterol, and other substances accumulate on the artery walls. It can lead to chest pain, heart attacks, or other serious cardiovascular complications.Coronary artery disease treatment typically includes lifestyle changes, medications like statins and antiplatelet drugs, and in severe cases, surgical procedures such as angioplasty or coronary artery bypass surgery. These therapies aim to reduce symptoms, prevent complications, and improve heart function.
Coronary Artery Disease Epidemiology
According to a study, in 2022, approximately 315 million people globally were affected by coronary artery disease (CAD), with notable regional variations. Central and Eastern Europe, along with Central Asia, exhibited high age-standardized prevalence (8,019 per 100,000). In the United States, coronary artery disease remains the most common heart disease, causing 371,506 deaths in 2022, with around 5% of adults impacted.Coronary Artery Disease Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of coronary artery disease drug candidates based on several segmentations, including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Small Molecules
- Monoclonal Antibodies
- Peptides
- Gene Therapies
- RNA-Based Therapies
By Route of Administration
- Oral
- Parenteral
- Others
Coronary Artery Disease - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase IV covers a major share of the total coronary artery disease clinical trials.Coronary Artery Disease Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the coronary artery disease pipeline analysis include small molecules, monoclonal antibodies, peptides, gene therapies, and RNA-based therapies. The coronary artery disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for coronary artery disease.Coronary Artery Disease Clinical Trials Therapeutic Assessment - Competitive Dynamics
The report for the coronary artery disease drug pipeline covers the profiles of key companies involved in clinical trials and their drugs under development. It provides a detailed coronary artery disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in coronary artery disease clinical trials:- Novartis Pharmaceuticals
- Honya Medical Inc.
- Beijing Inno Medicine Co., Ltd.
- Ribocure Pharmaceuticals AB
- Elixir Medical Corporation
- MedTrace Pharma A/S
- iVascular S.L.U.
- CoreAalst BV
- GE Healthcare
- NewAmsterdam Pharma
- Verve Therapeutics, Inc.
- Hanmi Pharmaceutical Co., Ltd.
Coronary Artery Disease Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for coronary artery disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of coronary artery disease drug candidates.Drug: Inclisiran sodium 300 mg
Novartis Pharmaceuticals is sponsoring a Phase IIIb study to evaluate Inclisiran’s efficacy in reducing atherosclerotic plaque progression in coronary artery disease patients. The study aims to assess plaque reduction through coronary computed tomography angiography (CCTA) over 24 months. Expected to be completed by January 2027, it includes approximately 608 participants receiving Inclisiran or placebo alongside statin therapy.Drug: RBD4059
The Phase IIa clinical trial, sponsored by Ribocure Pharmaceuticals AB, aims to evaluate the safety, pharmacokinetics, and pharmacodynamics of RBD4059 in participants with stable coronary artery disease. The study will assess potential side effects and efficacy compared to a placebo. With an estimated enrollment of 30 participants, the trial is expected to conclude by December 31, 2025.Drug: VERVE-102
Verve Therapeutics, Inc. is sponsoring a Phase 1b clinical study, evaluating the safety of VERVE-102 in patients with heterozygous familial hypercholesterolemia or premature coronary artery disease. The study aims to assess the drug's safety and pharmacodynamic profile by utilizing base-editing technology to disrupt the PCSK9 gene expression in the liver. The study is expected to be completed by August 2026 with an enrollment of around 36 participants.Reasons To Buy This Report
The Coronary Artery Disease Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for coronary artery disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into coronary artery disease collaborations, regulatory environments, and potential growth opportunities.Key Questions Answered in the Coronary Artery Disease - Pipeline Insight Report
- Which companies/institutions are leading the coronary artery disease drug development?
- What is the efficacy and safety profile of coronary artery disease pipeline drugs?
- Which company is leading the coronary artery disease pipeline development activities?
- What is the current coronary artery disease commercial assessment?
- What are the opportunities and challenges present in the coronary artery disease drug pipeline landscape?
- What is the efficacy and safety profile of coronary artery disease pipeline drugs?
- Which company is conducting major trials for coronary artery disease drugs?
- Which companies/institutions are involved in coronary artery disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in coronary artery disease?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Coronary Artery Disease
4 Patient Profile: Coronary Artery Disease
5 Coronary Artery Disease: Epidemiology Snapshot
6 Coronary Artery Disease: Market Dynamics
7 Coronary Artery Disease: Key Facts Covered
8 Coronary Artery Disease, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Coronary Artery Disease Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Coronary Artery Disease Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Coronary Artery Disease Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Coronary Artery Disease Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Coronary Artery Disease, Key Drug Pipeline Companies
